The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Therapeutic and diagnostic implications of Hsp90 activation
Open accessAbstract
The molecular chaperone heat-shock protein 90 (Hsp90) is involved in the stabilization and conformational maturation of many signaling proteins that are deregulated in cancers. Hsp90 inhibition results in the proteasomal degradation of these client proteins and leads to potent antitumor activity. The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is presently in clinical trials. Recent work has identified the role of Hsp90 in multiple signal transduction pathways and revealed that the molecular mechanism of tumor selectivity by Hsp90 inhibitors is the result of an activated, high-affinity conformation of Hsp90 in tumors. This review discusses these recent advances in the understanding of tumor Hsp90 for the treatment and diagnosis of cancer. In addition, the role of Hsp90 in non-oncological diseases will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270
Morimoto, R. I. (1998) · Genes & Development · doi:10.1101/gad.12.24.3788 · Cited by 1,906
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Zou, J., Guo, Y., Guettouche, T., Smith, D. F., & Voellmy, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81588-3 · Cited by 1,232
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4829 · Cited by 735
In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Obermann, W. M. J., Sondermann, H., Russo, A. A., Pavletich, N. P., & Hartl, F. U. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.4.901 · Cited by 601
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1
Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J. K., Singh, S., Millson, S. H., Clarke, P. A., Naaby-Hansen, S., Stein, R., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00785-2 · Cited by 542
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Meyer, P., Prodromou, C., Hu, B., Vaughan, C., Roe, S. M., Panaretou, B., Piper, P. W., & Pearl, L. H. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00065-0 · Cited by 491
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Schulte, T. W., Blagosklonny, M. V., Ingui, C., & Neckers, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24585 · Cited by 456
Sittler, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1307 · Cited by 442 · cited 1×
“In addition to ischemic injury, there is evidence that Hsp90 inhibitors could be utilized in protein-aggregation diseases of the CNS, such as Huntington's disease (HD), because nanomolar concentrations of geldanamycin activated a heat-shock response and inhibited HD protein aggregation in a cell-culture model for HD […”
BackgroundStress management – heat shock protein-70 and the regulation of apoptosis
Beere, H. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01874-2 · Cited by 435
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
Unusual expression and localization of heat‐shock proteins in human tumor cells
Ferrarini, M., Heltai, S., Zocchi, M. R., & Rugarli, C. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510418 · Cited by 432
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones
Prodromou, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.754 · Cited by 425
Xu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37
Roe, S. M., Ali, M. M. U., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2004) · Cell · doi:10.1016/s0092-8674(03)01027-4 · Cited by 349
Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase.
Hu, J., & Seeger, C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1060 · Cited by 323
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 307
Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Pharmacological prevention of Parkinson disease in Drosophila
Auluck, P. K., & Bonini, N. M. (2002) · Nature Medicine · doi:10.1038/nm1102-1185 · Cited by 280
Bagatell, R., Paine-Murrieta, G. D., Taylor, C. W., Pulcini, E. J., Akinaga, S., Benjamin, I. J., & Whitesell, L. J. (2000) · PubMed · Cited by 269
An, W. G., Schulte, T. W., & Neckers, L. Μ. (2000) · PubMed · Cited by 267
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Whitesell, L. (1996) · Molecular Endocrinology · doi:10.1210/me.10.6.705 · Cited by 263
Nimmanapalli, R., O’Bryan, E., & Bhalla, K. N. (2001) · PubMed · Cited by 242
McLaughlin, S. H., Smith, H. W., & Jackson, S. E. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5245 · Cited by 242
The Assembly of Progesterone Receptor-hsp90 Complexes Using Purified Proteins
Kosano, H., Stensgard, B., Charlesworth, M. C., McMahon, N., & Toft, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32973 · Cited by 240
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., & Sawyers, C. L. (2002) · Blood · doi:10.1182/blood-2002-05-1361 · Cited by 227
Grenert, J. P., Johnson, B. D., & Toft, D. O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17525 · Cited by 225
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 202
Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90
Jez, J. M., Chen, J. C.-H., Rastelli, G., Stroud, R. M., & Santi, D. V. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00075-9 · Cited by 197
Chiosis, G., Lucas, B., Shtil, A., Huezo, H., & Rosen, N. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00253-5 · Cited by 195
O'Keeffe, B., Fong, Y., Chen, D., Zhou, S., & Zhou, Q. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.279 · Cited by 177
ATPases as drug targets: learning from their structure
Chène, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd894 · Cited by 163
Fumo, G., Akin, C., Metcalfe, D. D., & Neckers, L. (2003) · Blood · doi:10.1182/blood-2003-07-2477 · Cited by 149
Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia
Lu, A., Ran, R., Parmentier‐Batteur, S., Nee, A. C., & Sharp, F. R. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00835.x · Cited by 145
Reconstitution of Progesterone Receptor with Heat Shock Proteins
Smith, D. F., Schowalter, D. B., Kost, S. L., & Toft, D. O. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-11-1704 · Cited by 144
Bonvini, P., Gastaldi, T., Falini, B., & Rosolen, A. (2002) · PubMed · Cited by 143
Blagosklonny, M. V., Fojo, T., Bhalla, K. N., Kim, J.-S., Trepel, J., Figg, W. D., Rivera, Y., & Neckers, L. M. (2001) · Leukemia · doi:10.1038/sj.leu.2402257 · Cited by 126
Expression and Roles of Heat Shock Proteins in Human Breast Cancer
Yano, M., Naito, Z., Tanaka, S., & Asano, G. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb02119.x · Cited by 116
Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller, P. E., DiOrio, C., Moyer, M. P., Schnur, R. C., Bruskin, A. M., Cullen, W., & Moyer, J. D. (1994) · PubMed · Cited by 113
Yao, Q., Nishiuchi, R., Li, Q., Kumar, A. R., Hudson, W. A., & Kersey, J. H. (2003) · PubMed · Cited by 111
Host cell factor requirement for hepatitis C virus enzyme maturation
Waxman, L., Whitney, M. A., Pollok, B. A., Kuo, L. C., & Darke, P. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241510898 · Cited by 93
Radicicol-sensitive Peptide Binding to the N-terminal Portion of GRP94
Vogen, S. M., Gidalevitz, T., Biswas, C., Simen, B. B., Stein, E. M., Gulmen, F., & Argon, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205323200 · Cited by 77
Li, Y., Tao, P., Liu, Y.-Z., & Jiang, J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.867-872.2004 · Cited by 73
Piatelli, M. J., Doughty, C. A., & Chiles, T. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200102200 · Cited by 72
Dymock, B. W., Barril, X., Beswick, M., Collier, A. J., Davies, N., Drysdale, M., Fink, A., Fromont, C., Hubbard, R. E., Massey, A. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.11.011 · Cited by 68
Neckers, L., & Lee, Y. S. (2003) · Nature · doi:10.1038/425357a · Cited by 64
Hatanaka, Y., Hashizume, K., Kamihara, Y., Itoh, H., Tsuda, H., OSAMURA, R. Y., & Tani, Y. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01162.x · Cited by 59
Heat shock protein-90, IL-6 and IL-10 in bladder cancer.
Cardillo, M. R., Sale, P., & Silverio, F. D. (2001) · PubMed · Cited by 58
Xu, L., Eiseman, J. L., Egorin, M. J., & D’Argenio, D. Z. (2003) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1025542026488 · Cited by 57
Conde, A. G., Lau, S. S., DILLMANN, W. H., et al. (1997) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1997.0431 · Cited by 56
Xiao, N., Callaway, C. W., Lipinski, C. A., Hicks, S. D., & DeFranco, D. B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720095.x · Cited by 55
Smith, V., Hobbs, S. M., Court, W., et al. (2002) · PubMed · Cited by 52
Yorgin, P. D., Hartson, S. D., Fellah, A. M., Scroggins, B. T., Huang, W., Katsanis, E., Couchman, J. M., Matts, R. L., & Whitesell, L. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.2915 · Cited by 52
Cited by
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698
Heat Shock Proteins and Cancer
Wu, J., Liu, T., Rios, Z., Mei, Q., Lin, X., & Cao, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.009 · Cited by 696
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Metadata
- Authors
- Kamal, A., Boehm, M. F., & Burrows, F. J.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 10
- Issue
- 6
- Pages
- 283-290
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2136966549
- Cited by
- 278
- References
- 67
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.